The estimated Net Worth of Charles Robert Evans is at least 525 千$ dollars as of 13 November 2015. Mr. Evans owns over 10,000 units of MiMedx Inc stock worth over 197,325$ and over the last 10 years he sold MDXG stock worth over 0$. In addition, he makes 327,925$ as Independent Director at MiMedx Inc.
Sign up
Mr. Evans MDXG stock SEC Form 4 insiders trading
Charles has made over 1 trades of the MiMedx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of MDXG stock worth 78,400$ on 13 November 2015.
The largest trade he's ever made was buying 10,000 units of MiMedx Inc stock on 13 November 2015 worth over 78,400$. On average, Charles trades about 1,429 units every 0 days since 2014. As of 13 November 2015 he still owns at least 31,878 units of MiMedx Inc stock.
You can see the complete history of Mr. Evans stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Evans biography
Charles R. Evans serves as Independent Director of the Company. Mr. Evans has over 40 years of experience in the healthcare industry. He is currently President of the International Health Services Group, an organization he founded to support health services development in underserved areas of the world. Since 2009, he has served as a senior adviser with Jackson Healthcare, a consortium of companies that provide physician and clinical staffing, anesthesia management and information technology solutions for hospitals, health systems and physician groups. In addition, Mr. Evans is a Fellow in the American College of Healthcare Executives having previously served as Governor of the College from 2004 to 2007 and as Chairman Officer from 2008 to 2011. In 2012, he attained the Board Leadership Fellow credential of the National Association of Corporate Directors. Previously, Mr. Evans was a senior officer with Hospital Corporation of America (HCA), having managed various HCA divisions and completing his service with the responsibility for operations in the Eastern half of the country. Mr. Evans currently serves on the board of directors of Jackson Healthcare and AnewMed Inc. Mr. Evans serves on the boards of nonprofit organizations including having served as past chairman of MedShare International, and Chairman of the Hospital Charitable Service Awards. Mr. Evans has served on the Board since 2012 and was nominated as a director due to his healthcare management expertise.
What is the salary of Charles Evans?
As the Independent Director of MiMedx Inc, the total compensation of Charles Evans at MiMedx Inc is 327,925$. There are 8 executives at MiMedx Inc getting paid more, with Timothy Wright having the highest compensation of 5,069,350$.
How old is Charles Evans?
Charles Evans is 73, he's been the Independent Director of MiMedx Inc since 2019. There are 2 older and 19 younger executives at MiMedx Inc. The oldest executive at MiMedx Group, Inc is Neil Yeston, 77, who is the Independent Director.
What's Charles Evans's mailing address?
Charles's mailing address filed with the SEC is C/O MIMEDX GROUP, INC., 1775 WEST OAK COMMONS COURT, NE, MARIETTA, GA, 30062.
Insiders trading at MiMedx Inc
Over the last 15 years, insiders at MiMedx Inc have traded over 15,165,698$ worth of MiMedx Inc stock and bought 1,553,718 units worth 4,191,559$ . The most active insiders traders include Fund Management Ltd.Okumus ...、Steve Gorlin、Parker H Petit. On average, MiMedx Inc executives and independent directors trade stock every 48 days with the average trade being worth of 487,865$. The most recent stock trade was executed by William Frank Iv Hulse on 13 March 2024, trading 20,381 units of MDXG stock currently worth 162,029$.
What does MiMedx Inc do?
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
What does MiMedx Inc's logo look like?
Complete history of Mr. Evans stock trades at MiMedx Inc
MiMedx Inc executives and stock owners
MiMedx Inc executives and other stock owners filed with the SEC include:
-
Timothy Wright,
Chief Executive Officer, Director -
Peter Carlson,
Chief Financial Officer -
Timothy R. Wright,
CEO & Director -
Dr. Robert Benjamin Stein M.D., Ph.D.,
Exec. VP of R&D -
Peter Martin Carlson CPA,
Chief Financial Officer -
William F. Hulse IV,
Gen. Counsel & Sec. -
Scott Turner,
Senior Vice President - Operations and Procurement -
Dr. Rohit Kashyap Ph.D.,
Exec. VP & Chief Commercial Officer -
Charles Evans,
Independent Director -
Neil Yeston,
Independent Director -
M. Kathleen Behrens Wilsey,
Independent Chairman of the Board -
James Bierman,
Independent Director -
K. Todd Newton,
Independent Director -
Charles Koob,
Director -
Jack Howarth,
Senior Vice President of Investor Relations -
Robert Stein,
Executive Vice President - Research and Development -
Rohit Kashyap,
Executive Vice President, Chief Commercial Officer -
Martin Sutter,
Independent Director -
William Hawkins,
Independent Director -
William Phelan,
Senior Vice President, Chief Accounting Officer -
William Hulse,
General Counsel, Secretary -
Mark Graves,
Chief Compliance Officer -
Scott M. Turner,
Sr. VP of Operations & Procurement -
Stan Micek,
Sr. VP of Bus. Devel. & Portfolio Management -
Dr. David H. Mason Jr.,
Chief Medical Officer -
Hilary Dixon,
VP of Investor Relations & Corp. Communications -
John J. Howarth,
Sr. VP of Investor Relations -
William L. Phelan,
Sr. VP & Chief Accounting Officer -
Larry W Papasan,
Director -
William Charles Taylor,
President and COO -
Michael J. Senken,
Chief Financial Officer -
Joseph G Bleser,
Director -
Parker H Petit,
Chairman & CEO -
J Terry Dewberry,
Director -
Bruce Hack,
Director -
Luis A Aguilar,
Director -
Fund 2 Holding Company, L.P...,
-
Mark Landy,
EVP & Chief Strategy Officer -
Fund Management Ltd.Okumus ...,
-
Edward Borkowski,
EVP & Interim CFO -
Tiffany Olson,
Director -
Kurt M Eichler,
Director -
Thomas J Koob,
Chief Scientific Officer -
Roberta L Mccaw,
General Counsel and Secretary -
Steve Gorlin,
Director -
Rebeccah Covert Brown,
-
Michael J Giuliani,
Director -
Cato T Laurencin,
Director -
M Kathleen Behrens,
Director -
Richard Barry,
Director -
Joseph H Capper,
Chief Executive Officer -
Phyllis Gardner,
Director -
Ricci S Whitlow,
Chief Operating Officer -
Todd Newton,
Director -
Rice Doug,
Chief Financial Officer -
Dorothy E Puhy,
Director